Global Ganja Report

The horrific case of an elderly Jewish woman in Paris killed in a clear anti-Semitic attack is being painted as an incidence of "cannabis delirium." Despite all the progress since the days of Reefer Madness in the 1930s, cannabis is still  blamed for violent crime by law enforcement and media alike. Such irrational ugliness has also been repeatedly seen in the cases that have inspired Black Lives Matter on our side of the Atlantic.

Several bills now pending before the Colorado state house will further shape what the legal cannabis economy will look like in the Centennial State—for better or for worse. While some of these measures would mean a freer atmosphere both for "recreational" and medicinal users, others may portend greater big-money control of the fast-growing industry.

Seniors are the fastest growing group of medicinal cannabis users in the coutry, and a growing number of nursing homes from coast to coast are tolerating use of tinctures and extracts to combat dementia, insomnia and related ailments. Patient testimony is now backed up by research, with scientists identifying the mechanism by which cannainoids slow the deterioration of neurons in the brain. But federal strictures continue to pose an obstacle to investigation—leaving medicinal users in the cold under US law.

Oakland-based cannabis industry research firm ArcView Group has released a new study, ambitiously entitled "The Road Map to a $57 Billion Worldwide Market." It provides a sweeping overview of recent progress and future prospects for legal or medical herb across the globe. But it also warns that, due to continued legal restrictions and bureaucratic overstretch, the market is in most areas bottlenecked from achieving its potential.

In a sure sign of changing times, the first cannabis-industry business has been listed on the NASDAQ stock exchange—raising clear questions about how long prohibition can hang on in the face of a burgeoning economic sector. Toronto-based medical marijuana producer Cronos Group won approval from the US Securities and Exchange Commission (SEC) to become the first cannabis company listed on NASDAQ, New York City's second biggest stock market, Bloomberg reported Feb. 26.

Even back in the bad old days of Reefer Madness in the 1930s, when marijuana's association with Mexican immigrants and African American musicians was used as propaganda for the first federal laws banning the weed, it never came to this. But the canard that cannabis is a tool in a sinister Jewish conspiracy to subvert wholesome white American youth has now entered (almost) mainstream discourse.

A welcome blow is reported against the deeply ingrained stigma that attaches even to users of basically harmless drugs like cannabis that happen to be illegal. The Global Commission on Drug Policy—a body with dissident views but made up of prestigious elder statesmen and world leaders, so it can't be readily ignored—has just issued a statement calling on policymakers and the media to avoid using terms such as "drug user," "addict" and "junkie." The report includes a checklist of what terms should be eschewed or embraced to avoid language portraying people who use drugs as "physically inferior or morally flawed."

Colombia, with a burgeoning medical marijuana industry, just saw its first international exposition on the theme, marking a step toward normalization of cannabis in a country hit hard by drug war violence over the past generations. The Medellín Botanical Garden was the scene of the ExpoMedeWeed from Nov. 24-27, with workshops and discussions on technical, medical and cultural themes related to expanding Colombia's legal cannabis sector. The affair won favorable coverage from major Colombian news outlets such as Bogotá daily El Espectador.